drugset / Trial / NCT00621842
Lamotrigine for Symptoms of Geriatric Bipolar Depression
Phase 3
Completed
57 enrolled
University Hospitals Cleveland Medical Center
GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression. Non-demented older adults with Bipolar I or II depression, confirmed via the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM) - Patient edition (SCID-I/P) and meeting inclusion criteria for depressive symptom severity (score of 18 or greater on the Hamilton Depression Rating Scale/HAM-D-24) will receive add-on lamotrigine dosed to a target of 200 mg/day.
Timeline
- Start
- 2008-01
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamotrigine | Small molecule | 200 mg | — |